Activation of Human Dendritic Cells by Ascophyllan Purified from Ascophyllum nodosum
1
Scientific Research Center, Shanghai Public Health Clinical Center & Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai 201508, China
2
Department of Chemistry, Pukyong National University, Busan 48513, Korea
3
Marine-integrated Bionics Research Center, Pukyong National University, Busan 48513, Korea
4
Department of Medical Biotechnology, Yeungnam University, Gyeongsan 38541, Korea
5
Research and Development Division, Hayashikane Sangyo Co., Ltd., Shimonoseki, Yamaguchi 750-8608, Japan
6
Graduate School of Science and Technology, Nagasaki University, Nagasaki 852-8521, Japan
7
Department of Biomedical Sciences, University of Ulsan College of Medicine, ASAN Medical Center, Seoul 05505, Korea
*
Authors to whom correspondence should be addressed.
†
These authors contributed equally to the work.
Mar. Drugs 2019, 17(1), 66; https://doi.org/10.3390/md17010066
Received: 27 December 2018
/
Revised: 16 January 2019
/
Accepted: 17 January 2019
/
Published: 19 January 2019
(This article belongs to the Collection Marine Polysaccharides)
In our previous study, we showed that ascophyllan purified from Ascophyllum nodosum treatment promotes mouse dendritic cell (DC) activation in vivo, further induces an antigen-specific immune response and has anticancer effects in mice. However, the effect of ascophyllan has not been studied in human immune cells, specifically in terms of activation of human monocyte-derived DCs (MDDCs) and human peripheral blood DCs (PBDCs). We found that the treatment with ascophyllan induced morphological changes in MDDCs and upregulated co-stimulatory molecules and major histocompatibility complex class I (MHC I) and MHC II expression. In addition, pro-inflammatory cytokine levels in culture medium was also dramatically increased following ascophyllan treatment of MDDCs. Moreover, ascophyllan promoted phosphorylation of ERK, p38 and JNK signaling pathways, and inhibition of p38 almost completely suppressed the ascophyllan-induced activation of MDDCs. Finally, treatment with ascophyllan induced activation of BDCA1 and BDCA3 PBDCs. Thus, these data suggest that ascophyllan could be used as an immune stimulator in humans.
View Full-Text
Keywords:
ascophyllan; dendritic cell activation; mitogen-activated protein kinase; T cell proliferation; peripheral blood dendritic cell
▼
Show Figures
Figure 1
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
MDPI and ACS Style
Zhang, W.; Kwak, M.; Park, H.-B.; Okimura, T.; Oda, T.; Lee, P.C.-W.; Jin, J.-O. Activation of Human Dendritic Cells by Ascophyllan Purified from Ascophyllum nodosum. Mar. Drugs 2019, 17, 66. https://doi.org/10.3390/md17010066
AMA Style
Zhang W, Kwak M, Park H-B, Okimura T, Oda T, Lee PC-W, Jin J-O. Activation of Human Dendritic Cells by Ascophyllan Purified from Ascophyllum nodosum. Marine Drugs. 2019; 17(1):66. https://doi.org/10.3390/md17010066
Chicago/Turabian StyleZhang, Wei, Minseok Kwak, Hae-Bin Park, Takasi Okimura, Tatsuya Oda, Peter C.-W. Lee, and Jun-O Jin. 2019. "Activation of Human Dendritic Cells by Ascophyllan Purified from Ascophyllum nodosum" Marine Drugs 17, no. 1: 66. https://doi.org/10.3390/md17010066
Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
